To determine which factors are associated with higher urethroplasty procedural costs and whether they have been increasing or decreasing over time.
Introduction
Urethral stricture disease affects roughly 5,000 new patients per year. [1] Common etiologies of urethral strictures include traumatic urethral injury, infections of the genitourinary tract, and/or prior lower urinary tract 3 instrumentation. The clinical implications of stricture disease include lower urinary tract symptoms, pain, urinary infections and ejaculatory dysfunction. [2] Urethral stricture disease may be managed with urethral dilation, urethrotomy, urinary diversion or urethroplasty. [3] Urethroplasty is considered the gold standard treatment for urethral stricture with high success rates. [4] Urethroplasty has also been shown to be a cost-effective management of urethral stricture disease. [5] Several studies have demonstrated that urethroplasty is costeffective for long strictures, recurrent strictures following internal urethrotomy, and virgin bulbar strictures. [5] [6] [7] Increasing attention to the development of a high value low cost healthcare system is a priority of United States (U.S.) policy makers as projections of healthcare costs in the U.S. are shown to be unsustainable. [8] Attention on healthcare cost reduction has been a major focus of policy efforts. [9] Cost-transparency is an important first step in targeting costcontainment efforts.
In surgical subspecialties, procedural costs and surgical outcomes are under increased scrutiny.
Efforts to minimize cost and maximize quality care have led to the development of quality reporting clearinghouses such as the NIS and NSQIP (National Surgical Quality Improvement Program). [10] Such programs allow for critical appraisal of healthcare delivery with a focus on optimizing quality at reduced cost. Recently the American Urological Association (AUA) announced its quality Page 3 of 28 registry termed AQUA whose focus will be quality improvement in prostate cancer management. [11] Utilizing this NIS data, we can critically evaluate the optimal drivers of cost associated with inpatient surgical procedures.
There remains a paucity of literature examining national urethroplasty trends and outcomes with most published data limited to single institutional series. [12] Furthermore, data on national variations in urethroplasty cost is lacking. Our objective is to examine this variation in urethroplasty cost and identify predictors of highest cost for urethroplasties admitted to U.S. hospitals. We hypothesize urethroplasty associated with extremes of cost is related to patient comorbidities and surgical complexity.
Methods

Data Source
We identified men in the National Inpatient Sample (NIS) database who underwent urethroplasty surgery between 2001 and 2010. The NIS is a database that captures 20% of hospital admissions within the U.S. Details on the methods of data capture and variance in NIS have been previously published. [13] 
Inclusion and Exclusion Criteria
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Male patients were included if they had both an International Classification of Disease (ICD-9) diagnosis code of urethral stricture disease and an ICD-9 procedural code for urethroplasty indicating that a urethroplasty was performed.
The ICD-9 diagnosis codes utilized for urethral stricture were 598, 598.0, 598.01, 598.1, 598.2, 598.8, and 598.9. ICD-9 procedural codes for urethroplasty We excluded patients who underwent a urethral dilation, urethral fistula repair, and those with an additional major surgical procedure(s) such as cystectomy.
Patients were categorized based upon the type of urethroplasty performed: buccal mucosa grafting (ICD-9 procedural codes 7.49, 27 [14] This report contains hospital-specific cost-tocharge ratios based upon all-payer inpatient costs for NIS participating hospitals.
To obtain cost estimates, we multiplied total charges with the appropriate cost-tocharge ratio.
We evaluated the following patient demographic characteristics: age (18-45, 45-65, and >65), race (Caucasian, African American, other), household income quartile (extrapolated from a patient's ZIP code), number of comorbidities (0, 1, 2, 3 or more), and type of comorbidity (e.g. diabetes, hypertension, obesity). We assessed the following hospital characteristics: hospital location (rural or urban), region of the hospital (Northeast, Midwest, South, West), hospital bed size (small, medium, large), and teaching status of the hospital (yes/no). We also examined payer status (Medicaid, private insurer, self-pay, or Medicare), urethroplasty volume of the surgeon (1, 2-9, or greater than 10 per year), the year the urethroplasty was performed, type of urethroplasty procedure, presence and type of a perioperative complication(s), and length of hospital stay.
Demographic definitions were all congruent with the current descriptions of data elements utilized by HCUP-NIS.
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Outcome Variables
The primary outcome variable was urethroplasty cost, specifically variables associated with the top 20 th percentile in urethroplasty cost, which was defined as Extreme Cost. Extreme cost was set at the top 20 th percentile of cost a priori.
As a post-hoc sensitivity analysis, we compared the outcome of the top 20 th percentile and 10 th percentile of cost and demonstrated no differences.
Statistical Analysis
Data analysis was performed using SAS (Version 9.2, SAS Institute Inc, Cary NC). Relative median cost (RMC) was used to compare differences in increased cost and Odds Ratios (OR) were used to compare extremes of cost. A log cost linear regression model was used to assess for variables associated with more costly urethroplasties. Multivariate analysis controlling for patient age, race, and year of urethroplasty was performed. Extremes of cost was defined as the top 20 th percentiles of all reported urethroplasties and were analyzed using multiple logistic regression with the same predictors as for log cost. A comparison was then performed between extreme of cost and increased cost to determine which variables were major drivers of cost. Cost of urethroplasty was higher in patients age 45-65 years relative to patients age 18-45 years (RMC 1.1, 95% CI 1.0-1.1, p=0.03). Conversely, patients older than 65 years were not more costly (RMC 1.0, 95% CI .95-1.10, p=.74). Patient race, patient income, and payor type were not independently associated with increased cost on univariate analysis. (Table 1) On multivariate analysis after controlling for age, race, and year of urethroplasty performed, there was a significantly higher cost of urethroplasty in higher volume urethroplasty centers. Compared to hospitals performing 1 urethroplasty/year, hospitals performing 2-9 and >10 urethroplasty/year were most costly (RMC 1. 
Results
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Predictors of High Cost Urethroplasty
Extremes of Cost Analysis
Multiple factors were associated with extreme cost which we categorized as the top 20 th percentile of costs. A rural hospital setting had more than three-fold higher odds of having extreme cost compared to an urban hospital setting (OR 3.5, 95% CI 1.3-9.3, p=0.01). Other graft use was associated with highest cost urethroplasty (OR 1.8, 95% CI 1.2-2.6, p=0.005) however buccal graft was not associated with extreme cost (OR 1.3, 95% CI 0.9-1.9) ( 
Discussion
To our knowledge this is the first report on cost variation in a national sample of urethroplasties. Two prior studies have tackled cost evaluation from the Page 11 of 28 perspective of optimum surveillance strategies for the postoperative management of urethral strictures. [15, 16] Here we analyze and begin to understand cost variations, specifically which factors are most strongly associated with increased urethroplasty cost among admitted patients, as this has important implications for healthcare resource utilization.
We demonstrate that patient comorbidities and postoperative complications are strong predictors of a more costly urethroplasty. This highlights the importance of optimizing patient comorbidities preoperatively in an effort to decrease postoperative complications and cost. We found that postoperative complications were major drivers of extereme cost urethroplasties. Supporting efforts to optimize patients for surgery in order to maximize outcomes and thus minimze complications is warranted.
Buccal graft and other grafting use was also associated with a higher cost urethroplasty and other graft use was associated with extreme cost urethroplasty. This is reflective of more complex urethral stricture disease that drives up procedural cost, complication rate, and length of hospital stay. We hypothesize that urethroplasty in patients over 65 were not more costly due to selection bias toward simpler urethral reconstructive techniques such as urethrotomy or urethral dilations which were excluded in this analysis and have been shown to be the most common procedure done for Medicare beneficiaries with urethral stricture disease over 65 years of age. [17] Page 12 of 28 We hypothesize that hospitals with an annual urethroplasty volume of two or more are associated with higher cost urethroplasty as they are more likely to perform complex urethral surgery and are more likely to utilize graft/flap procedures compared to hospitalize performing only one urethroplasty per year.
Also, hospitals coded as performing one urethroplasty a year may suffer from accidental mis-coding.
When examining the extremes of cost, a rural hospital setting was more than three times the cost compared to an urban hospital setting. We hypothesize that this is the result of rural settings having less specialty trained urethral reconstructive surgeons and lower volume of complex urethral surgical cases compared to larger referral center which are usually located in urban or suburban settings. [18] Studies have consistently shown increased length of stay and hospital costs for complex procedures performed in rural settings. [19] Interestingly, hospital bed size e.g. a smaller number of beds was not found to be predictive of a urethroplasty of higher cost or extreme cost.
Despite a trend toward more costly urethroplasty being performed at teaching hospitals, multivariate analysis demonstrated no significant differences when compared to cost of urethroplasty at nonteaching institutions. This is congruent with current data suggesting that increased trainee oversight amounts to equal cost, quality and patient satisfaction at teaching institutions. [20] We hypothesize Page 13 of 28 that despite more complex urethroplasties being performed at teaching hospitals, the cost may be offset by attending oversight rendering improved quality and/or patient satisfaction.
Cost reduction efforts are only part of the solution in optimizing healthcare delivery. Other policy efforts include increasing value of healthcare by improving the metrics of healthcare outcomes and patient satisfaction. Quality indicators of urethral stricture disease have previously been explored. [21] A shift in focus on cost-conscious, high value healthcare is a priority for U.S. policy makers as current healthcare expenditures are unsustainable. [22] Identifying which aspects of perioperative care and the impact of presurgical patient optimization will be criticial for cost reduction. Current data suggests that preoperative intervention strategies can reduce postoperative complications and therefore surgery- There are several study limitations within this study. First, NIS data is crosssectional and based on procedural coding and thus does not include information on urethral stricture disease etiology. It is well known that stricture etiology such as lichen sclerosis, reoperative strictures, or longer stricture length are Page 14 of 28 preoperative factors associated with complex flap/graft urethroplasty and increased complication rates and hospital stay. [24] [25] [26] [27] Second, the NIS data is limited to the immediate inpatient stay after urethroplasty. Outpatient or shortstay related procedures may not be captured by this dataset depending on coding differences across hospitals. As a result, there is selection bias toward morbid patients who require admission following urethroplasty. Longer-term complications, types of complications, readmissions, and/or urethroplasty outcomes are also not accounted for such that NIS data is lacking granularity.
However, long-term success rates of urethroplasty are high [12, 28] and delayed complications from urethroplasty are rare. [29] Therefore, the downstream cost of stricture recurrence is unlikely to be a major driver of total urethroplasty cost.
Third, we subcategorized anastomotic urethroplasty if a buccal grafting procedural code was not utilized. This may falsely overestimate the number of anastomotic procedures rendered nationally. Lastly, only inpatient complications during the initial perioperative hospital admission period were captured thus missing complications from outpatient surgical centers and some 23-hour stay patients might not be included based on coding differences across hospitals.
Similarly, readmissions following urethroplasty were not captured. Understanding which patients have such long term complicating features would allow for a more sensitive subgroup analysis to determine drivers of cost.
Conclusion
Page 15 of 28 We demonstrate that cost variation for perioperative inpatient urethroplasty procedures is dependent on preoperative patient comorbidities, postoperative complications and usage of grafting. Identification of extreme cost variation has policy implications to reduce healthcare costs meanwhile maintaining quality.
Further evaluation of long-term outcomes of outpatient urethroplasty is needed to fully understand predictors of extreme cost given that the majority of urethroplasties are performed on an outpatient basis. Urethroplasty in most instances is a cost-effective treatment for recurrent urethral stricture. However, urethroplasty has an associated cost and this should be minimized whenever possible. This manuscript by Osterberg et al. is an interesting study examining hospital based urethroplasty costs using the HCUP-NIS database. Over a nine-year period 2298 inpatient urethroplasties were examined to determine variations in urethroplasty cost and identify factors associated with "extreme costs" (defined as the top 20th percentile of expenditure). There is a paucity of information on this topic and as cost control in healthcare becomes more important these types of studies will become extremely relevant. On multivariate analysis the authors found that patients with multiple co-morbid conditions, graft-based urethroplasties and the occurrence of inpatient complications were the factors associated with extreme urethroplasty cost. This is a useful contribution to the existing literature; however, it is interesting that these cost associations may not actually be under a urologists control. Seldom can we change the fact that patients have these co-morbid conditions. Given that elderly patients and patients with other morbidities likely benefit from urethroplasty, it would be difficult and perhaps immoral to deny these patients the benefits of urethroplasty. [1] On balance it seems that proper patient selection and optimally treating pre-existing medical conditions would be prudent. It thus behooves the reconstructive urologist to maintain a holistic approach to our surgical decision-making. Graft usage was also associated with increased urethroplasty cost. Using a graft during urethroplasty typically depends on the length and location of the urethral stricture. It is these patients with longer strictures that are least amenable to endoscopic measures or anastomotic urethroplasty. Thus, avoiding grafts based urethroplasty is likely not usually possible. However, this data might suggest that it would be prudent to use an anastomotic urethroplasty technique whenever technically feasible and clinically appropriate. Lastly, it would be valuable if factors associated with urethroplasty complications could be identified, given that the occurrence of inpatient complications was the factor most strongly associated with extreme urethroplasty cost. There is currently a paucity of studies examining what increases the risk of urethroplasty complications. It is likely that most series underestimate the true prevalence of urethroplasty complications. Urethroplasty complications have been reported as high as 40% with wound complications, neuralgia, infectious complications and minor voiding or sexual dysfunction being most commonly reported. [2] [3] [4] While these complications are typically transient and mostly well tolerated, reducing these complications may sometimes be as simple as modifying the type of incision, surgical technique or changing suture materials.
[5] Fortunately most (>90%) urethroplasty complications are minor, however, complications Clavien 3 or greater may occur in up to 8% of patients undergoing urethroplasty. [4] These high-grade complications are most commonly related to infection, bleeding, thrombo-embolism or wound related events. [2] [3] [4] [5] Although the occurrence of these complications may be happenstance, further research examining factors predisposing to complications requiring readmission and prolonged hospitalization appears warranted in order to minimize morbidity and eliminate unnecessary urethroplasty cost.
